Arvinas, Inc.
(NASDAQ : ARVN)

( )
ARVN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.37%283.400.0%$3951.53m
BNTXBioNTech SE -3.55%291.940.0%$1261.44m
NVAXNovavax, Inc. -0.60%181.7578.2%$864.57m
AMGNAmgen, Inc. 1.05%213.531.4%$651.58m
LGVNLongeveron Inc. 11.85%21.900.0%$515.31m
GILDGilead Sciences, Inc. 0.09%69.711.0%$515.13m
VRTXVertex Pharmaceuticals, Inc. 0.68%206.611.9%$454.10m
REGNRegeneron Pharmaceuticals, Inc. 2.98%654.042.7%$419.38m
ILMNIllumina, Inc. 1.77%375.983.3%$351.77m
SNSSSunesis Pharmaceuticals, Inc. 1.16%4.360.7%$304.78m
BIIBBiogen, Inc. 3.48%234.721.8%$297.97m
SGENSeagen Inc. 2.12%149.555.8%$157.99m
EXASEXACT Sciences Corp. 3.48%86.2618.0%$150.95m
INCYIncyte Corp. 0.90%67.332.4%$147.13m
BMRNBioMarin Pharmaceutical, Inc. 2.62%88.384.2%$138.75m

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.